Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Beigene Ltd (ADR) before investing.

In this article, we go over a few key elements for understanding Beigene Ltd (ADR)’s stock price such as:

• Beigene Ltd (ADR)’s current stock price and volume
• Why Beigene Ltd (ADR)’s stock price changed recently
• Upgrades and downgrades for BGNE from analysts
• BGNE’s stock price momentum as measured by its relative strength

About Beigene Ltd (ADR) (BGNE)

Before we jump into Beigene Ltd (ADR)’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Want to learn more about Beigene Ltd (ADR)’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Beigene Ltd (ADR).

Beigene Ltd (ADR)’s Stock Price as of Market Close

As of September 12, 2024, 4:00 PM, CST, Beigene Ltd (ADR)’s stock price was $196.27.

Beigene Ltd (ADR) is down 7.05% from its previous closing price of $211.15.

During the last market session, Beigene Ltd (ADR)’s stock traded between $205.60 and $215.00. Currently, there are 104.70 million shares of Beigene Ltd (ADR) stock available for purchase.

Unfortunately, Beigene Ltd (ADR)’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Beigene Ltd (ADR) Stock Price History

Beigene Ltd (ADR)’s (BGNE) price is currently up 2.34% so far this month.

During the month of September, Beigene Ltd (ADR)’s stock price has reached a high of $215.00 and a low of $186.03.

Over the last year, Beigene Ltd (ADR) has hit prices as high as $215.00 and as low as $126.97. Year to date, Beigene Ltd (ADR)’s stock is down 10.76%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Beigene Ltd (ADR) Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 11, 2024, there were 0 analysts who downgraded Beigene Ltd (ADR)’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Beigene Ltd (ADR)’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Beigene Ltd (ADR)’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Beigene Ltd (ADR)’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Beigene Ltd (ADR) (BGNE) by visiting AAII Stock Evaluator.

Relative Price Strength of Beigene Ltd (ADR)

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 11, 2024, Beigene Ltd (ADR) has a weighted four-quarter relative price strength of 1.52%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Beigene Ltd (ADR) is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Beigene Ltd (ADR) Stock Price: Bottom Line

As of September 12, 2024, Beigene Ltd (ADR)’s stock price is $196.27, which is down 7.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Beigene Ltd (ADR) stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.